We describe a novel steroid, which we have named "Ionotropin". Its unique features are: [1] it has 23 carbon atoms and [2] it is a phosphocholine ester. There are no other known mammalian steroids with either structural feature. Ionotropin cross reacts with digoxin-specific antibodies and may be the long-sought, endogenous, mammalian digoxin-like material (DLM). Using LC-MS, we identified three other phosphocholine steroids in serum. Two of these steroids also cross-react with digoxin specific antibodies.
Introduction
In the 18th century, Withering observed that extracts from foxglove (Digitalis lanata) were useful for treating dropsy, a disease we now call congestive heart failure [1] . Digoxin, the active principle from foxglove, has two domains: (1) tri-digitoxose, commonly called the glycone, and (2) cardiotonic steroid, commonly called the aglycone (not the glycone). Szent-Gyorgyi proposed that digoxin wasn't really a drug but was really a substitute for an endogenous unknown hormone [2] . Digoxin has been a difficult drug in medical practice because it has a low therapeutic index. The ratio of the toxic level to the therapeutic level is only three. Partly for this reason, an RIA was developed for digoxin [3] . The goal was to monitor serum digoxin levels to avoid toxicity. Pretreatment, apparent digoxin levels were less than 0.05 ng/mL. Serum levels necessary for therapy must exceed 0.6 ng/mL but levels over 2.0 ng/mL were associated with toxicity.
When the digoxin assay became available, there were occasional reports of cross reacting materials (DLM) in individuals who had not been treated with digoxin [4] . In the last 20 years, there have been more than 200 reports (including seven from my laboratory) of an unknown DLM or OLM in patients with hypertension, pre-eclampsia, renal failure and other disorders of electrolyte regulation [5] .
Ouabain is the cardiotonic steroid glycoside isolated from oleander (Nerium oleander). Some investigators have used antibodies specific for ouabain to detect ouabain like-materials (OLM). It is not clear if there is a difference between DLM and OLM. Using the OLM assay, an OLM was isolated from human plasma [6] . The authors claimed that the NMR of the isolated material was indistinguishable from authentic ouabain but ouabain has not been widely accepted as the endogenous cardiotonic steroid [7] . Moreover, LC-MS-MS and CD analysis does not confirm the presence of ouabain in human serum [8] [9] [10] .
In this paper we describe the isolation and characterization of novel steroids from porcine blood and bovine adrenal extracts. As the original isolation was based on cross-reaction with digoxin-specific antibodies and digoxin regulates the NaK-ATPase to accumulate potassium electrolytes, we propose Ionotropin to designate the active compound. Based on the known adrenal enzymatic pathways, we propose a biosynthetic pathway that leads to Ionotropin. Finally, a review of data suggests that Ionotropin functions as an endogenous potassium sparing hormone. No known endogenous compound has a similar function.
Methods

Digoxin immunoassay
Standard solutions, containing known amounts of digoxin, were prepared by diluting standards provided by the manufacturer (Dupont, Boston). Standard curves were prepared by adding 0.1 mL of each standard (0.05, 0.1, 0.2,0.5, 1.0 & 2.0 ng/mL) to 12 × 75 mm borosilicate culture tubes (Fisher Scientific). Samples to be evaluated were pipetted into 12 × 75 mm tubes and evaporated to dryness under a stream of dry nitrogen and dissolved in 0.1 mL of the zero standard. 0.2 mL of [125-I]-labeled digoxin-tracer and 0.2 mL of digoxin antibody were added to each tube. The tubes were mixed by vortex and allowed to incubate at room temperature for 30 min. Thereafter, the tubes were centrifuged at 2600×g for 30 min, decanted, and blotted. [125-I] was evaluated with a gamma counter. Individual values were determined by interpolation against the best fit standard curve and expressed as ng of digoxin equivalents (ngE) [11] .
Analytical LC-MS method
Samples for analysis were mixed with acetonitrile and filtered with Whatman Syringe nylon filters with 0.2 µm pore size. The column used was an amino carbohydrate column purchased from All-tech, Chicago, IL (3.9 mm × 300 mm, 10 µm). The MS was operated in APCI positive ion mode; cone voltage 75 V; 180 C. Nitrogen was the nebulizing gas. The LC-MS work station used MassLynx software. Table 1 shows the gradient used for analytical purposes. At the completion of the gradient, the column had returned to its starting solvent and a new sample was injected with the auto-injector. Data is presented as generated by the software.
Source of tissues and blood
The following tissues and blood samples were purchased from Pel Freez Biologicals ( 0  5  9 5  2  2 5  7 5  12  45  55  14  60  40  16  60  40  17  5  95  20  5  95 Solvent Composition: A = water/acetonitrile (99:1); B = acetonitrile; Flow = 0.5 mL/min; Injection loop volume = 10 µL. unidentified disorders in sexual development and [6] 3 patients with PCO. The samples were collected at an academic clinical and research laboratory in New York State that had IRB approval to use residua from samples submitted. Except for PCO, DLM has not been reported as occurring in patients with any of these diagnoses and all were considered 'normal' and analyzed as a single group. The samples from girls with PCO were evaluated as a separate group. Breast cyst fluids were residua of samples collected by fine needle biopsy as part of normal patient care. The analytical procedure was as follows:
[a] 0.1 mL of serum from a patient sample was pipetted into a 12x75 mm tube, [b] to each tube 0.4 mL of acetonitrile was added, [c] each tube was vortexed, [d] the sample was filtered through a syringe filter, and [e] subject to LC-MS after transfer to an injection vial (MS was Waters, APCI in the positive ion mode). Accelerating voltages were adjusted to minimize fragmentation.
Extracts containing DLM
The tissue or blood was homogenized with a mixture of acetonitrile/ water, to yield a final ratio of about 4:1. The extract was filtered crudely on Whatman #1 filter paper and centrifuged. In batches, the extract was applied to a preparative amino carbohydrate HPLC column (22x500 mm) from Alltech (Chicago). Aliquotes of each fraction were tested with a saturated silver nitrate reagent. When the test was positive (white precipitate forms), the application of the crude extract was terminated and the column eluted with a 40 min gradient of water/ acetonitrile (20/80) to water/acetonitrile (60/40). Individual fractions were analyzed by LC-MS. Fractions containing phosphocholine esters were combined and concentrated under vacuum. After each batch, the column was washed with water/acetonitrile (95/5) and then restored to starting condition with water/acetonitrile (5/95). Pooled fractions were dissolved in water/acetonitrile (5/95) and the chromatography repeated with a slower gradient. Three passes were necessary to get a single peak. The final step was isocratic elution at water/acetonitrile (18/82). Starting with 10 L of pig blood, after drying under vacuum, the final sample weighed about 8 mg. If the isolation process recovered 50% of the amount in pig blood, then the original serum concentration was about 1.6 mg/L (160 µg/dL) or 3 µM. NMR spectra were obtained by Acorn Laboratories (Livermore, CA). Ionotropin was also present in serum samples obtained from humans, horse, pigs, cattle, sheep, chickens, turkeys, dogs, goats, rabbits, rats and mice. For each animal serum sample, an extract was made, filtered and chromatographed. Fractions were collected, dried under vacuum, and assayed for DLM by immunoassay and for Ionotropin by LC-MS. Both methods identified the same fractions and there were no fractions that contained one without the other. Although not detailed here, PC steroids were also purified to > 90% homogeneity from humans, turkeys, and egg whites. Fig. 1 shows the LC-MS analysis of Ionotropin isolated from porcine blood. The peak shape suggests that it is at least 95% pure with, possibly, a small impurity on the trailing edge. The total ion count (TIC) chromatogram would have detected any contaminating positive ions. No contaminants were detected in negative ion spectrum. The MS-LC specific ion chromatograms all show peaks at the same retention time as the TIC peak. In the positive ion spectrum, we expected to observe three counter ions, H + , Na + , and K + . Thus, to identify the true protonated molecule, there should be peaks at M + 1, M + 23, M + 39 and this pattern is present. Thus, the molecule with m/z = 524 Da is the protonated cation. The peak shape distortion might be caused by a slight difference in retention time of the three cations.
LC-MS fragmentation pattern for Ionotropin
Fragmentation analysis
The most common fragment of Ionotropin had a mass of 184 Da. This fragment is characteristic of phosphocholine esters, such as sphingomyelin. As a model compound, DHEA-PC was synthesized [12, 13] and its mass spectrum is shown in Fig. 2 . The molecular mass of DHEA is 288 Da. The steroid fragment would be 271 Da with the M + 1 confirm that Ionotropin is a phosphocholine ester. There are no known steroid PC esters, other than the ones described in this presentation. When we increased the cone voltage of the MS, more of the Ionotropin fragmented. However, other than the PC fragment, there was only one other fragment -at 341 Da, equivalent to M-182 Da, just like the model compound, DHEA-PC. The corresponding mass for the parent steroid fragment would be 358 Da. There are no previously known steroids with a mass of 358 Da. The lack of other small fragments derived from the steroid at higher cone voltage is not surprising because at least two breaks would be needed to generate a fragment. Table 2 shows a trial and error (Edisonian) examination of all possible elemental compositions for the steroid portion of Ionotropin. Here are the basic rules for the analysis: a. Molecules containing only carbon, hydrogen and oxygen must have "even" molecular weights. b. H-max is the maximum number of hydrogens possible in a molecule and is equal to twice the number of carbons plus two. The actual number of hydrogens (H-req) in a molecule is decreased by twice Δ where Δ is the number of double bonds and rings in the molecule. Hydroxy groups don't change the number of hydrogens, but carbonyl groups count as a Δ. c. A steroid must have Δ greater than four because of the 4 fused rings.
Molecular composition of Ionotropin
Unless a steroid has multiple conjugated double bonds, such as an estrogen, Δ is unlikely to exceed 8.
The only composition that satisfies these guidelines is C 23 H 34 O 3 . However, there are no known mammalian steroids with 23 carbon atoms.
PC esters in human sera samples
When we investigated Ionotropin levels in human serum samples, we found Ionotropin was not the only PC steroid ester. Fig. 4 shows LC-MS data from one of the 42 samples. The particular sample presented was obtained from a patient with CAH. Table 3 shows how the major peaks in the chromatograms can be attributed to four PC steroids. For each compound, there were three molecular ion peaks, one for each of the cationic forms -H + , Na + , and K + . Table 4 tabulates the relative peak heights of the 4 PC steroid esters in the 42 human samples. The pediatric population was selected because the "one disease to a customer" guideline in pediatrics would be expected to reduce patient to patient variability. In fact, the only clinical group that was statistically different from the overall group was the three samples from patients with PCO. The narrow range of variability, with a standard deviation of about 15% of the mean, indicates that Ionotropin is not secreted in periodic pulses in contrast to the secretory patterns for ACTH and glucocorticoids. The implied half-life of Ionotropin must be in the range of days, rather than the 20-minute half-life of most other steroids. The observation that the PC pattern is different in patients with PCO may be an important "anecdote." The pattern suggests a partial defect in biosynthesis. Finally, the observation that Ionotropin was detected by LC-MS in patients with CAH is an important confirmation of our earlier observation of DLM in patients with this inborn error [14] . Further, both digoxin and ouabain have 21-hydroxy groups and "endogenous" ouabain could not be synthesized in patients with CAH due to 21-hydroxylase deficiency.
Isolation of other PC esters
Compounds II, III, and IV were isolated from side fractions obtained during the isolation of Ionotropin from pig blood. Each of the compounds was confirmed as a PC ester on the basis of a characteristic PC fragment at m/z = 184 Da, a base peak characteristic of the steroid fragment and three peaks associated with typical serum electrolyte cations (H + , Na Fig. 5 ) had a molecular ion at m/z = 522 Da, two less than that observed for Ionotropin. 6 shows the spectra obtained with the four steroid PC esters. The spectra were obtained in deuterated methanol (CD 3 OD). Most of the hydrogens have corresponding chemical shifts in the four spectra. For example, the chemical shift of the PC hydrogens is between 3.8 and 4.5 and the peak pattern in that range is the same for all four compounds. The hydrogens added when the alkenes are reduced will join the other approximately 20 hydrogen atoms with a chemical shift between 1.4 and 2. Overall, the spectra indicate that the four samples are relatively pure and are closely related. Fig. 7 shows the LC-MS analysis of the crude adrenal extract. We did not separate the cortex and medulla, but homogenized the whole adrenals. There was a second peak in the TIC chromatogram that did not contain PC esters. The extract was loaded onto the preparative column and each fraction was analyzed by LC-MS. The numbers on the figure identify the fractions that contained the material at that retention time. The four PC esters were mostly in fraction 19 and that material was used for their isolation. Fraction 22 contained a material at a retention time of approximately 10 min which was not associated with a PC fragment. Fig. 8 shows MS data obtained at 9.8 min and 9.9 min of the LC-MS chromatogram. No PC esters were present at that time point in the chromatogram. However, mass ions associated with each of the four steroid fragments were present. Table 6 summarizes the m/z assignments. In summary, although we have not yet purified to near homogeneity each of the four PEs, for each PC, there was a corresponding PE ester that was identified by LC-MS analysis.
PE esters in bovine adrenal extracts
Discussion
There are two themes in the discussion: First, the biochemistry: Fig. 9 shows the proposed structures of the phosphosteroids and Fig. 10 shows the complete pathway including the unconjugated steroid precursors. Ionotropin is the first steroid discovered since aldosterone. Second, the endocrinology: Ionotropin as the potassium sparing hormone. In view of the dogma that ouabain is the endogenous cardiotonic steroid, the isolation and characterization data are presented as actually generated by the instruments. The discussion of the endocrinology is particularly important as it defines some of the functions for Ionotropin. I  524  546  562  184  341  358  Yes  II  522  544  560  184  339  356  Yes  III  520  542  558  184  337  354  Yes  IV  496  518  534  184  313  330  No Note:
The spectrometer was set to record the range from 400 Da to 600 Da. Within this range the largest peak was at 496 Da. The major peaks could be assigned to four compounds, designated as I, II, III, and IV. Compound I is Ionotropin. Each of the four compounds has been purified to near homogeneity. Notes: Ratios are presented as mean ± standard deviation; DLM was below the level detected with the immunoassay for digoxin; Roman numerals identify compounds as detailed in Table 3 ; Compound I is Ionotropin.
Biochemistry: Ionotropin vs ouabain
In 1991, with an assay developed for ouabain, investigators isolated an ouabain-like material (OLM) [6] . The isolated 'ouabain' was reported to inhibit NaK-ATPase. However, the endogenous ouabain had a different CD spectrum than plant derived ouabain [10] . When this was reported, the active compound was described as 'endogenous' OLM rather than as 'endogenous ouabain.' The concentration of OLM isolated from human plasma was 100 ng/L or 0.1 ng/mL. The half-life of ouabain is less than 20 min [15] . In order to maintain a serum level that would be functional (0.4 ng/mL), daily production would need to exceed 2 mg/day and that amount is known to be toxic. Baecher tried to measure serum levels with an ultra-sensitive LC-MS-MS method. The lower limit of detection was about 0.8 ng/L but no ouabain could be detected [8] . Several investigators have shown that OLM was present in adrenal extracts and that the amount increased on incubation [16, 17] . However, these studies did not characterize the product other than that it cross-reacted with an ouabain-specific antibody. Hamlyn notes the need for the development of analytical methods that use clinically relevant volumes of blood for the routine determination of DLM [17] . Nicholls suggests that immunoassay data are not sufficient for the claim of endogenous ouabain [18] . There must also be direct chemical evidence for precursors or metabolites. The LC-MS method can be adapted to monitor Ionotropin levels on individual samples and provide the needed direct chemical evidence on small sample. In contrast to the studies claiming the isolation of OLM, which did not detect any other precursors or metabolites, this study identifies a total of eight compounds that together form a pathway to Ionotropin. Table 8 compares the physical properties of ouabain to those of Ionotropin.
In a 2004 review, Hamlyn suggests that three unknown steps would be needed to synthesize his proposed cardiotonic steroids from either cholesterol or pregnenolone [17] . Two of the steps require inversion of an isomer (at carbon 5 and at carbon 14), but there are no enzymes known that catalyze similar steps. The third step is the formation of the E-ring, including a 21-hydroxy substituent. If that was part of the process, then patients with 21-hydroxylase deficiency (CAH) would not be able to synthesize either endogenous OLM or DLM. However, as shown in Fig. 4 , patients with CAH synthesize Ionotropin. Thus, Ionotropin does not have an E-ring similar to ouabain or digoxin and Hamlyn's proposed pathway does not describe the synthesis of Ionotropin.
The estimated serum concentration provides an estimate of the binding affinity of Ionotropin at its receptor. To provide the greatest responsiveness the binding affinity would be similar to the normal serum concentration, about 3 µM. This concentration rules out a major site of action in a nuclear receptor, like the progesterone receptor, which has a binding affinity of less than 6 nM. For comparison, normal adult serum concentration of DHEA-S is 200-400 µg/dL or 10 µM. Thus, the estimated serum concentration of Ionotropin is within the concentration range observed with other steroid hormone conjugates. For comparison, Hamlyn isolated 10 µg ouabain from 80 L of normal human serum, equivalent to 0.2 nM [6] . For ouabain to function it must have a corresponding affinity at the receptor site and may even be a suicide inhibitor. If so, functional activity could not be restored until new proteins were synthesized, a slow process. Thus, it is hard to visualize a mechanism for Ionotropin and ouabain to function by the same receptor. (1) by cleavage of a 4 carbon fragment from a 27 carbon sterol, or (2) by addition of a 2 carbon fragment to a 21-carbon steroid. The biosynthesis of pregnenolone from cholesterol is catalyzed by the cholesterol side chain cleavage enzyme. Burstein [19] showed that the side chain fragment has 6 carbon atoms and that there were no smaller fragments. Thus, the pathway to 23 carbon steroids must go through a steroid with 21 carbon atoms by addition of two carbon atoms. Compound IV is the only phosphoester we found that has 21 carbons and could be the base for the addition of a two-carbon fragment. Slominski [20] showed that 7-dehydrocholesterol (compound A) is also a substrate for the side chain cleavage enzyme -leading to pregna-5,7-dienolone (Compound B). Compound B is a substrate of 17α-hydroxylase, in turn leading to formation of pregna-5,7-diene-3-17α-diolone (Compound C) [21] . The stereo specificity of 17-hydroxylase was confirmed as 17α-hydroxylase by crystallization to constant specific activity [22] . Shackleton showed that Compounds B and C are present in human serum, but his methods did not identify anyphosphoesters [23] .
Phosphoester formation
There are two pathways for the biosynthesis of PC esters: [a] salvage and [b] de novo. In the salvage pathway, the intact PC group would be transferred directly to the steroid. The two paths can be distinguished by the presence or absence of PE esters. PE esters would be part of the de novo pathway but would not be part of the salvage pathway. As shown in Table 7 , adrenal extracts contained PE esters corresponding to Compounds I, II, III, and IV. Thus, the de novo pathway must be used. N-methylation would be necessary to convert the PEs to PCs. Occam's Razor suggests that, as no other steroid phosphoesters have ever been 
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Steroids 136 (2018) [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] described in any species, it is likely that the pathway of biosynthesis includes all of the compounds we discovered. The alternative would mean that there was another, as yet, unreported or undiscovered pathway.
The structure of Compound IV
To get to m/z = 330 Daltons, Compound IV must have 21 carbon atoms, three oxygens with Δ = 7. Pregnenolone contributes Δ = 6 (4 rings, a ketone and a Δ5 alkene). The only steroid hydroxylase that uses Δ5, 3β-hydroxy steroids as substrate is the 17α-hydroxylase [22] . There are 17β-steroids, but these are made by reduction of the corresponding 17-ketone. Juxtaposition of the 17α-hydroxy group with the 20-ketone would be necessary to form a lactone ring after a malonylCoA condensation (24) . The only question remaining about the structure of compound IV is the location of the seventh Δ element. The UV spectrum suggests the presence of a conjugated π structure. The only one known would be the Δ7 position, just as is present in the proximal cholesterol precursor, Compound A. This matches the steroid identified by Shackleford in patients with SLO.
Formation of the E-ring from Compound IV
To form Ionotropin, we need to add two carbon atoms to compound IV, to get a steroid with 23 carbon atoms, Compound III. It would be formed by addition of malonyl-CoA at the 20-ketone, loss of carbon dioxide and ring closure. A similar mechanism is believed to be responsible for the synthesis of the E-ring of digoxin by foxglove leaves (25) . The malonyl CoA condensation is well known for the extension of fatty acids, but whether or not this same enzyme is actually used for the condensation and closure of the E-ring lactone in Ionotropin has not been evaluated.
Reduction of the B-ring
The final two steps are the reduction of the alkene bonds (Δ5 and Δ7) in the steroid B-ring. Each of the reductases twists the steroid closer to the structure of the plant aglycones. (Maybe the plants use that structure to interfere with the mammalian receptor). A comparison of the 3D structures of the Compounds I, II, and III, with the 3D structure of digoxin indicates that only Compound I has a structure like that of digoxin. The biochemistry of these reductases has been poorly investigated. The Δ7 reductase is part of the cholesterol biosynthesis pathway and is found in the liver and the adrenal, but not in patients with SLO. The reduction of the Δ5 alkene is required for the biosynthesis of cholic acid in the liver and leads to 5β-compounds but is not required for the synthesis of any common steroid. For example, in the biosynthesis of 5α-dihydro-testosterone, the Δ5 alkene is reduced in two steps. First, the 3β-hydroxy is oxidized to the ketone and isomerized to the Δ4, 3-ketone. In the second step, the Δ4 alkene is reduced to form a 5α-steroid. This two-step mechanism cannot be part of the biosynthetic pathway to Ionotropin because the PC ester occupies the 3-position. Thus, Ionotropin seems to be a 5β steroid because there is no direct pathway to 5α-steroids without a Δ4,3-keto intermediate and such an intermediate could not be a PC ester. Fig. 11 shows a 3D representation of the difference in structure between the 5α and 5β isomers. This structural difference could prevent steroids with the 5α structure from binding at the site of Ionotropin binding. The key point to acknowledge is whether or not the proposed structures are correct does not change the correlation with the chemical formulas determined by the Edisonian analysis for compounds Ionotropin, II, III, and IV. The proposed structures are consistent with known enzymatic processes but still require confirmation by synthesis. That confirmation may occur when (if) Ionotropin is synthesized for hormonal replacement therapy as it is difficult to visualize a natural source sufficient for that purpose. In the interim, the LC-MS methodology should be sufficient for diagnostic purposes as it does not depend on the stereochemistry.
Endocrinology of Ionotropin
The classical steroids (progesterone, testosterone, aldosterone and glucocorticoids) were all discovered prior to 1960. Each of these hormones was recognized by their physiology, isolated, and structures determined. For Ionotropin, the story is just starting and it will be many years before the physiology of Ionotropin is as well-known as the classical steroids. The following sections speculate on possible biological activities of Ionotropin.
Ionotropin in patients with SLO
Our laboratory evaluated patients with potential steroid biosynthetic defects. In 1983, one patient, in addition to the morphology characteristic of SLO, had potassium wasting and extremely high levels of steroids detected with antibodies to DHEA-sulfate and 17-hydroxyprogesterone [26, 27] . This was the first report of a possible steroid defect in patients with this syndrome. To characterize the steroids, serum was extracted with aqueous methanol and chromatographed. Each fraction was assayed with an antibody specific for steroid sulfates. Two peaks were detected. One peak had DLM and the other did not. Table 6 for the m/z assignments. At other retention times there was a different mixture of the PE-steroids, confirming the existence of all four steroid PE esters. However, when we evaluated a serum sample from a normal, 3-day old infant, four steroids were detected, three were DLM and one was not. Serum from normal 30 day old infants had undetectable DLM levels. In 1995, Tint showed that SLO syndrome was caused by 7-sterol reductase deficiency [28] . Thus, the two missing compounds must occur in the biosynthetic pathway after the 7-sterol reductase step [27] . The recognition of the defect in SLO was a key step in understanding the biosynthetic pathway to Ionotropin.
Review of Ionotropin (DLM) during gestation and the neonatal period
To characterize the novel compounds, we needed a rich source. The first potential source investigated was cord serum. The cord serum had DLM and steroid sulfate levels similar to that observed in the 3-day old infants [29] . Recently, we re-examined the data [30] . During the third trimester of pregnancy, aldosterone synthesis and signaling are both blocked [31] . This coincides with the known increase in DLM that occurs at this stage of gestation [32, 33, 34] . After parturition, while the DLM levels were high, the infants were salt-wasting and losing weight. By 2 weeks of age, DLM levels were undetectable; the infants were not salt-wasting and were gaining weight. The weight loss and the lack of growth in the first week of life have long been known, but the underlying physiology was unknown. This pattern suggests that Ionotropin, the active component of DLM, acts just like a synthetic potassium sparing drug (e.g. spironolactone) and blocks aldosterone signaling, leading to salt-wasting. When the fetal-placenta relationship ends at parturition, synthesis of Ionotropin decreases and serum levels decrease to normal for both the infants and mothers. This points to a combined role of the fetal adrenal and placenta for the biosynthesis of Ionotropin, perhaps much like the synthesis of estriol. Whether or not there are any long-standing changes in PC steroid levels after parturition is unknown. Such changes may contribute to the increased long-term risk of coronary heart disease in women and infants who were affected by preeclampsia.
Synthetic potassium sparing diuretics (e.g. spironolactone) have two functions: (a) increasing blood pressure and (b) increasing potassium recovery in the kidney. Ionotropin seems to have both functions. As the fetus grows, fetal peripheral resistance increases. The fetus responds by increasing Ionotropin synthesis, leading to increased fetal blood pressure. But that is only half the story. As the fetus grows, it requires more potassium for its intracellular fluids. The signal from the fetus would be Ionotropin secretion from the placenta. Maternal Ionotropin would lead to increased K + recovery in the renal circulation, in turn leading to increased plasma levels of K + to the placenta. Fetal blood K + levels are somewhat higher than the maternal levels [35] . Inadequate fetal K + from any cause would be expected to lead to excess secretion of Ionotropin, in turn leading to maternal hypertension and proteinuria. At parturition, the fetal-placental source of Ionotropin would be eliminated and blood pressure would return to pre-pregnancy levels. This seems to describe the natural history of pre-eclampsia.
DLM in human breast fluids
Historically, breast cysts have been investigated as a possible risk factor for breast cancer [36] . There are two types of cysts characterized by their electrolyte composition. Type 1 fluids have K + levels in the 40-100 mM range and Na + levels in the 10-20 mM range. Type 2 fluids have low levels of K + , about 10 mM and Na + levels in the range of 50-100 mM. The initial studies suggested that women with Type 1 cysts had greater than a 5-fold increased risk for breast cancer compared to women with Type 2 cysts. Together with Bradlow, DLM levels were evaluated in both types of fluids [11] . Type 1 fluids had DLM levels of 0.6 ngE/ml while DLM was undetectable in Type 2 fluids. Pools (100 mL) of Type 1 fluids were extracted and chromatographed. The high concentration of DLM permitted development of improved methods whereas the methods used to isolate 'endogenous' ouabain as described by Hamlyn were not successful [6] . The Type 1 cysts have both high K + levels and high Ionotropin levels. As both the Ionotropin and the high K + ions are inside the Type 1 cyst, the Ionotropin must be stimulating K + accumulation against the electrolyte gradient from the extracellular fluids. Thus, Ionotropin is functioning as a potassium sparing hormone in the Type 1 cysts. Human breast milk has high K + levels (15-20 mM) but the mechanisms that control monovalent ion concentration are not well understood [37] . The high concentration of Ionotropin in Type 1 breast cyst fluids points to a potential role in the process. From a practical standpoint, two questions need to be explored. First, does Ionotropin survive the pasteurization process? Second, is there a corresponding potassium sparing hormone in soy milk formulas? There might be benefit to Ionotropin supplementation for infants who are not growing at optimal rates. The suggestion of Ionotropin as an endogenous potassium sparing hormone has some important consequences. First, Ionotropin levels might divide hypertensive patients into two disease groups and guide selection of therapeutic programs. This would be an important step in individualizing therapy. Second, diseases that benefit from synthetic potassium sparing diuretics might have inadequate Ionotropin levels. Third, because of its long half-life, Ionotropin might be a better therapeutic agent than synthetic compounds with the same function.
Summary
This paper describes Ionotropin. It is the first report of a new class of steroid hormones. The hormones are unique in three ways: (1) cholesterol is not a precursor, (2) the steroids are phosphorylated, and (3) the lead compound, Ionotropin, has 23 carbon atoms. No other steroid hormone has any of these characteristics. Ionotropin seems to function as a potassium sparing hormone. It is the first example of an endogenous compound with this function. Ionotropin qualifies as a hormone as it: (1) is synthesized in the adrenal and placenta, (2) can be readily detected in plasma and (3) functions in the kidney, heart, and mammary gland. 
Funding
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